# Theranova Randomized, Controlled, Trial (RCT) in China

Study · id `cardio:ct-nct05309291` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05309291](<https://clinicaltrials.gov/study/NCT05309291>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05309291

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 323 participants.

## Technical summary

Registry record NCT05309291. Randomized; no masking; primary purpose treatment. Start 2022-06-22 (actual); primary completion 2023-07-06 (actual). Results posted on 2024-10-15.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 323 participants (enrolled count; ClinicalTrials.gov record NCT05309291, source copy `cardio:ctgov-nct05309291-2025-07-14`, retrieved 2026-10-26)
- Started: 2022-06-22 (actual) (ClinicalTrials.gov record NCT05309291, source copy `cardio:ctgov-nct05309291-2025-07-14`, retrieved 2026-10-26)
- Primary completion: 2023-07-06 (actual) (ClinicalTrials.gov record NCT05309291, source copy `cardio:ctgov-nct05309291-2025-07-14`, retrieved 2026-10-26)
- Completion: 2023-07-06 (actual) (ClinicalTrials.gov record NCT05309291, source copy `cardio:ctgov-nct05309291-2025-07-14`, retrieved 2026-10-26)
- Results first posted: 2024-10-15 (ClinicalTrials.gov record NCT05309291, source copy `cardio:ctgov-nct05309291-2025-07-14`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05309291, source copy `cardio:ctgov-nct05309291-2025-07-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05309291-2025-07-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Theranova Randomized, Controlled, Trial (RCT) in China
- Acronym: ROCKet
- Condition: Chronic Kidney Failure
- Condition: Acute Kidney Failure
- Intervention (Device): Theranova 400 Dialyzer
- Intervention (Device): FX 800 Dialyzer
- Lead sponsor: Vantive Health LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Baxter Healthcare Corporation
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Vantive Health LLC (`cardio:org-vantive-health-llc`)
- Registry lists this organization as a collaborator: Baxter Healthcare Corporation (`cardio:org-baxter-healthcare-corporation`)

## Provenance

Content hash: 966b2ada07b16293b6254d1b2d88a346f32532ada4e448be94ece7aea37f780e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
